Please login to the form below

Not currently logged in
Email:
Password:

Celgene poaches Sanofi Pasteur’s medical director

Adrian Kilcoyne announced as David Gillen’s replacement

Dr Adrian Kilcoyne has left his role as UK medical director at Sanofi Pasteur to join Celgene in the same role.

Taking on his new position this week, Dr Kilcoyne replaces Dr David Gillen who is promoted to head of global drug safety and risk management at Celgene.

He had been UK medical director at Sanofi's vaccines business Sanofi Pasteur since 2011, having joined the company from Roche where he was also medical director.

Other former roles include medical director at Baxter Healthcare and senior clinical research physician at Lilly.

This position at Lilly – which he took on in 2006 – was the first step in Dr Kilcoyne's pharma career and followed several years in primary and secondary care, as well as a spell as a specialist registrar in public health medicines at the Oxford Deanery.

Celgene's general manager for the UK Sam Pearce said: “He brings with him a wealth of experience that will prove a significant addition to the team, enabling us to continue to build on the already great work we are doing."

12th November 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics